GSK China Executive, Office Probe Subjects By Changsha Authority
This article was originally published in PharmAsia News
GlaxoSmithKline (China) Investment is under investigation by local authorities in Changsha, China for "suspicion of economic crimes" of an unnamed high-level executive.
You may also be interested in...
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.